Go Pro
→ BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it? (From Awesomely) (Ad)tc pixel Free BFRIW Stock Alerts

Biofrontera (BFRIW) Financials

Biofrontera logo
$0.04 +0.02 (+77.72%)
As of 07/21/2026 03:08 PM Eastern
Compare
Annual Income Statements for Biofrontera

Annual Income Statements for Biofrontera

This table shows Biofrontera's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -38 -0.64 -20 -18 -11
Consolidated Net Income / (Loss)		 -11 -38 -0.64 -20 -18 -11
Net Income / (Loss) Continuing Operations		 -11 -38 -0.64 -20 -18 -11
Total Pre-Tax Income 		-11 -38 -0.61 -20 -18 -11
Total Operating Income		 -9.61 -25 -19 -23 -17 -11
Total Gross Profit		 19 24 29 17 19 31
Total Revenue		 19 24 29 34 37 42
Operating Revenue		 19 24 29 34 37 42
Total Cost of Revenue		 0.00 0.00 0.00 17 19 11
Operating Cost of Revenue		 - - - 17 19 11
Total Operating Expenses		 28 49 47 39 36 42
Selling, General & Admin Expense		 18 37 35 39 34 38
Research & Development Expense		 - - 0.00 0.08 2.09 3.72
Total Other Income / (Expense), net		 -1.32 -12 18 2.56 -0.53 0.84
Interest Expense		 2.87 0.34 0.20 0.00 0.32 0.00
Interest & Investment Income		 - 0.00 1.75 -7.89 -2.05 -0.45
Other Income / (Expense), net		 1.55 -12 16 10 1.84 1.29
Income Tax Expense		 0.06 0.06 0.03 0.01 0.02 0.03
Basic Earnings per Share		 ($479.48) ($4.28) ($0.61) ($13.02) ($3.22) ($1.04)
Weighted Average Basic Shares Outstanding		 22.92M 8.81M 1.06M 1.55M 5.52M 10.17M
Diluted Earnings per Share		 ($479.48) - ($0.61) ($13.02) ($3.22) ($1.04)
Weighted Average Diluted Shares Outstanding		 22.92M 8.81M 1.06M 1.55M 5.52M 10.17M
Weighted Average Basic & Diluted Shares Outstanding		 22.92M 8.81M 26.70M 5.09M 8.87M 11.65M

Quarterly Income Statements for Biofrontera

This table shows Biofrontera's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.34 3.53 -10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75
Consolidated Net Income / (Loss)		 -6.34 3.53 -10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75
Net Income / (Loss) Continuing Operations		 -6.34 3.53 -10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75
Total Pre-Tax Income 		-6.34 3.52 -10 -0.24 -5.67 -1.40 -4.20 -5.30 -6.64 5.64 -4.75
Total Operating Income		 -4.62 -3.87 -5.47 -5.07 -4.96 -1.71 -4.55 -5.08 -6.28 4.56 -4.32
Total Gross Profit		 4.31 5.23 3.80 3.50 4.14 7.29 5.32 6.39 4.94 14 7.97
Total Revenue		 8.90 11 7.91 7.84 9.01 13 8.59 9.03 6.99 17 10
Operating Revenue		 8.90 11 7.91 7.84 9.01 13 - 9.03 6.99 17 10
Total Cost of Revenue		 4.59 5.37 4.12 4.34 4.88 5.27 3.27 2.64 2.05 3.01 2.12
Operating Cost of Revenue		 4.59 5.37 4.12 4.34 4.88 5.27 3.27 2.64 2.05 3.01 2.12
Total Operating Expenses		 8.93 9.09 9.26 8.57 9.10 9.00 9.87 11 11 9.54 12
Selling, General & Admin Expense		 8.69 9.06 9.25 7.95 8.43 8.22 8.66 11 10 8.75 11
Research & Development Expense		 0.03 0.03 0.02 0.62 0.67 0.78 1.21 0.87 0.85 0.79 0.90
Other Operating Expenses / (Income)		 - - - - - - - - - - 0.39
Total Other Income / (Expense), net		 -1.72 7.39 -4.97 4.83 -0.71 0.31 0.34 -0.22 -0.37 1.08 -0.43
Interest & Investment Income		 -2.35 -1.11 -1.40 -0.61 0.01 -0.04 -0.11 -0.11 -0.11 -0.12 -0.13
Other Income / (Expense), net		 0.63 8.38 -3.25 5.44 -0.71 0.36 0.45 -0.11 -0.26 1.20 -0.31
Income Tax Expense		 0.00 -0.01 0.00 0.02 0.00 -0.00 -0.00 0.02 0.01 -0.00 0.00
Basic Earnings per Share		 ($4.64) $2.28 ($2.88) ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41)
Weighted Average Basic Shares Outstanding		 1.37M 1.55M 3.62M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M
Diluted Earnings per Share		 ($4.64) $2.28 ($2.88) ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41)
Weighted Average Diluted Shares Outstanding		 1.37M 1.55M 3.62M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M
Weighted Average Basic & Diluted Shares Outstanding		 1.52M 5.09M 5.09M 5.54M 7.75M 8.87M 9.45M 10.67M 11.65M 11.65M 12.80M

Annual Cash Flow Statements for Biofrontera

This table details how cash moves in and out of Biofrontera's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.83 16 -7.33 -16 4.56 0.49
Net Cash From Operating Activities		 -12 -27 -16 -25 -10 -13
Net Cash From Continuing Operating Activities		 -12 -27 -16 -25 -10 -13
Net Income / (Loss) Continuing Operations		 -11 -38 -0.64 -20 -18 -11
Consolidated Net Income / (Loss)		 -11 -38 -0.64 -20 -18 -11
Depreciation Expense		 0.14 0.12 0.10 0.09 0.42 0.14
Amortization Expense		 0.42 0.42 1.07 0.98 0.73 0.73
Non-Cash Adjustments To Reconcile Net Income		 0.74 1.98 -11 4.94 0.13 -0.21
Changes in Operating Assets and Liabilities, net		 -2.69 8.48 -6.00 -11 6.21 -3.48
Net Cash From Investing Activities		 0.00 -0.01 -5.16 0.62 -0.00 3.00
Net Cash From Continuing Investing Activities		 0.00 -0.01 -5.16 0.62 -0.00 3.00
Purchase of Property, Plant & Equipment		 0.00 -0.01 -0.04 -0.01 -0.01 -0.00
Acquisitions		 - - - 0.00 -0.05 0.00
Sale of Property, Plant & Equipment		 - - - - 0.00 3.00
Sale and/or Maturity of Investments		 - - 0.00 0.62 0.06 0.00
Net Cash From Financing Activities		 13 43 14 8.41 15 11
Net Cash From Continuing Financing Activities		 13 43 14 8.41 15 11
Repayment of Debt		 8.79 - 0.00 -21 -0.27 0.00
Repurchase of Preferred Equity		 - - - 0.00 7.66 0.00
Issuance of Debt		 - - 0.00 25 7.44 0.00
Issuance of Preferred Equity		 - - - 0.00 0.00 11
Cash Interest Paid		 3.07 0.00 0.00 0.15 1.73 0.01
Cash Income Taxes Paid		 0.06 0.06 0.03 0.02 0.02 0.03

Quarterly Cash Flow Statements for Biofrontera

This table details how cash moves in and out of Biofrontera's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.03 -2.08 2.47 0.56 -1.51 3.03 -4.12 5.45 -3.82 2.98 -0.08
Net Cash From Operating Activities		 -2.00 -8.87 -3.33 -4.72 -1.21 -1.02 -4.12 -3.05 -3.82 -2.38 -0.07
Net Cash From Continuing Operating Activities		 -2.00 -8.87 -3.33 -4.72 -1.21 -1.02 -4.12 -3.05 -3.82 -2.38 -0.07
Net Income / (Loss) Continuing Operations		 -6.34 3.53 -10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75
Consolidated Net Income / (Loss)		 -6.34 3.53 -10 -0.26 -5.67 -1.40 -4.20 -5.32 -6.65 5.64 -4.75
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.36 0.03 0.02 0.02 0.07 0.06
Amortization Expense		 0.23 0.27 0.29 0.29 0.29 -0.14 0.19 0.20 0.19 0.15 0.13
Non-Cash Adjustments To Reconcile Net Income		 3.28 -4.62 4.19 -5.45 1.36 0.03 -0.24 0.14 0.73 -0.85 0.69
Changes in Operating Assets and Liabilities, net		 0.81 -8.07 2.62 0.67 2.79 0.13 0.10 1.92 1.89 -7.39 3.80
Net Cash From Investing Activities		 0.38 0.07 0.00 -0.00 - -0.00 -0.00 -0.00 0.00 3.00 -0.01
Net Cash From Continuing Investing Activities		 0.38 0.07 0.00 -0.00 - -0.00 -0.00 -0.00 0.00 3.00 -0.01
Purchase of Property, Plant & Equipment		 - 0.01 -0.06 -0.00 - 0.05 -0.00 -0.00 0.00 0.00 -0.01
Net Cash From Financing Activities		 0.59 6.71 5.80 5.28 -0.30 4.05 0.00 8.50 - 2.35 0.00
Net Cash From Continuing Financing Activities		 0.59 6.71 5.80 5.28 -0.30 4.05 0.00 8.50 - 2.35 0.00

Annual Balance Sheets for Biofrontera

This table presents Biofrontera's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 24 53 51 28 22 29
Total Current Assets		 20 46 43 23 21 18
Cash & Equivalents		 8.08 25 17 1.34 5.91 6.39
Short-Term Investments		 - 0.00 11 0.08 0.01 0.01
Accounts Receivable		 3.29 12 7.41 5.16 5.32 7.29
Inventories, net		 7.09 4.46 7.17 11 6.65 1.43
Prepaid Expenses		 1.12 4.99 0.81 0.43 0.53 2.28
Other Current Assets		 - - 0.00 5.16 2.30 0.69
Plant, Property, & Equipment, net		 0.37 0.27 0.20 0.13 0.08 2.16
Total Noncurrent Assets		 4.19 6.53 7.54 4.72 1.32 8.32
Intangible Assets		 3.87 3.45 3.03 2.63 0.04 2.65
Other Noncurrent Operating Assets		 0.32 0.27 1.70 2.09 1.29 5.67
Total Liabilities & Shareholders' Equity		 24 53 51 28 22 29
Total Liabilities		 18 42 27 23 18 18
Total Current Liabilities		 4.42 14 21 18 12 12
Accounts Payable		 4.42 11 13 13 11 12
Other Current Liabilities		 0.00 0.00 0.50 0.69 0.55 0.33
Total Noncurrent Liabilities		 14 28 6.11 5.05 5.65 6.19
Long-Term Debt		 - - - 0.00 4.10 4.59
Other Noncurrent Operating Liabilities		 14 28 6.11 5.05 1.55 1.60
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.83 11 24 4.79 4.43 10
Total Preferred & Common Equity		 5.83 11 24 4.79 4.43 10
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 5.83 11 24 4.79 4.43 10
Common Stock		 47 90 103 104 122 138
Retained Earnings		 -41 -79 -80 -100 -117 -128

Quarterly Balance Sheets for Biofrontera

This table presents Biofrontera's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 34 25 22 19 17 20 15 25
Total Current Assets		 30 20 17 17 15 19 14 13
Cash & Equivalents		 3.42 3.82 4.38 2.87 1.79 7.24 3.42 6.32
Short-Term Investments		 3.34 0.02 0.01 0.01 0.01 0.01 0.01 0.01
Accounts Receivable		 6.51 3.69 3.50 4.87 4.03 3.96 3.00 3.88
Inventories, net		 16 6.91 3.95 6.53 6.53 4.03 4.33 1.23
Prepaid Expenses		 0.27 0.56 0.47 0.35 0.68 0.33 0.63 1.06
Other Current Assets		 - 5.16 5.16 2.30 2.30 3.25 3.03 0.66
Plant, Property, & Equipment, net		 0.15 0.12 0.10 0.08 0.06 0.04 0.02 2.18
Total Noncurrent Assets		 4.34 4.30 4.00 1.50 1.20 1.29 0.98 9.45
Intangible Assets		 2.72 2.56 2.45 0.04 0.03 0.03 0.02 2.61
Other Noncurrent Operating Assets		 1.62 1.74 1.55 1.46 1.17 1.26 0.96 6.84
Total Liabilities & Shareholders' Equity		 34 25 22 19 17 20 15 25
Total Liabilities		 33 26 11 13 16 25 18 19
Total Current Liabilities		 29 14 9.27 11 11 20 13 11
Accounts Payable		 20 11 8.27 10 11 11 12 10
Other Current Liabilities		 0.56 0.69 0.70 0.67 0.43 8.94 0.31 0.51
Total Noncurrent Liabilities		 3.94 12 1.40 1.95 5.16 5.12 5.44 7.79
Long-Term Debt		 - - - - 4.22 4.34 4.46 4.72
Other Noncurrent Operating Liabilities		 3.94 12 1.40 1.95 0.94 0.79 0.98 3.08
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.04 -5.42 11 5.53 0.47 -4.67 -2.58 6.07
Total Preferred & Common Equity		 1.04 -5.42 11 5.53 0.47 -4.67 -2.58 6.07
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.04 -5.42 11 5.53 0.47 -4.67 -2.58 6.07
Common Stock		 104 105 121 122 122 122 131 139
Retained Earnings		 -103 -110 -110 -116 -122 -127 -134 -133

Annual Metrics And Ratios for Biofrontera

This table displays calculated financial ratios and metrics derived from Biofrontera's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 11,600,000.00 26,699,002.00 1,517,628.00 7,749,211.00 11,648,323.00
DEI Adjusted Shares Outstanding		 0.00 580,000.00 1,334,950.00 1,517,628.00 7,749,211.00 11,648,323.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -65.02 -0.48 -13.26 -2.29 -0.90
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 27.86% 18.98% 18.82% 9.54% 11.75%
EBITDA Growth		 0.00% -390.83% 97.31% -1,029.96% -27.40% 35.37%
EBIT Growth		 0.00% -363.29% 94.21% -466.11% -25.71% 34.55%
NOPAT Growth		 0.00% -162.35% 26.27% -22.04% 24.11% 34.06%
Net Income Growth		 0.00% -243.25% 98.30% -3,045.47% 11.78% 40.67%
EPS Growth		 0.00% 0.00% 0.00% -2,034.43% 75.27% 67.70%
Operating Cash Flow Growth		 0.00% -115.98% 39.36% -53.68% 58.75% -30.10%
Free Cash Flow Firm Growth		 0.00% 0.00% -162.25% 22.85% 63.21% -89.35%
Invested Capital Growth		 0.00% -342.50% 130.75% 137.47% -64.00% 230.97%
Revenue Q/Q Growth		 0.00% 0.00% 3.53% 1.34% 5.55% 12.22%
EBITDA Q/Q Growth		 0.00% 0.00% 91.45% 43.32% -71.90% 43.63%
EBIT Q/Q Growth		 0.00% 0.00% 82.11% 42.43% -61.86% 41.43%
NOPAT Q/Q Growth		 0.00% 0.00% -25.19% 7.18% 11.12% 35.58%
Net Income Q/Q Growth		 0.00% 0.00% 94.82% 23.87% -38.34% 40.04%
EPS Q/Q Growth		 0.00% 0.00% 94.82% 32.71% -45.05% 36.20%
Operating Cash Flow Q/Q Growth		 0.00% -318.21% 43.98% -2.45% 43.32% -11.32%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 8.56% 43.24% -71.98%
Invested Capital Q/Q Growth		 0.00% 0.00% 282.27% 128.59% -1.13% 660.67%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 48.80% 50.14% 73.71%
EBITDA Margin		 -39.75% -152.59% -3.45% -32.77% -38.11% -22.04%
Operating Margin		 -50.96% -104.57% -64.80% -66.56% -46.11% -27.21%
EBIT Margin		 -42.73% -154.83% -7.53% -35.89% -41.19% -24.12%
Profit (Net Income) Margin		 -58.29% -156.49% -2.23% -59.09% -47.58% -25.26%
Tax Burden Percent		 100.59% 100.15% 105.26% 100.07% 100.12% 100.24%
Interest Burden Percent		 135.62% 100.92% 28.15% 164.52% 115.39% 104.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -307.04% -243.50% -140.76%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -260.59% -1,951.12% 2.23%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 166.61% -141.48% -0.54%
Return on Equity (ROE)		 -188.52% -439.39% -3.63% -140.43% -384.98% -141.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -849.73% -388.51% -149.37% -247.94%
Operating Return on Assets (OROA)		 -33.37% -96.47% -4.15% -31.03% -61.45% -39.72%
Return on Assets (ROA)		 -45.52% -97.50% -1.23% -51.08% -70.99% -41.59%
Return on Common Equity (ROCE)		 -188.52% -439.39% -3.63% -140.43% -384.98% -141.30%
Return on Equity Simple (ROE_SIMPLE)		 -188.52% -332.62% -2.68% -420.01% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.72 -18 -13 -16 -12 -7.94
NOPAT Margin		 -35.67% -73.20% -45.36% -46.59% -32.28% -19.05%
Net Nonoperating Expense Percent (NNEP)		 -52.76% -136.63% 58.73% -46.45% 1,707.62% -142.99%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -182.52% -141.21% -52.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 51.20% 49.86% 26.29%
SG&A Expenses to Revenue		 93.94% 154.39% 122.54% 114.84% 90.66% 92.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.23% 5.60% 8.92%
Operating Expenses to Revenue		 150.96% 204.57% 164.80% 115.36% 96.26% 100.92%
Earnings before Interest and Taxes (EBIT)		 -8.05 -37 -2.16 -12 -15 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.49 -37 -0.99 -11 -14 -9.19
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 3.09 7.69 1.02 0.88 1.91 0.63
Price to Tangible Book Value (P/TBV)		 9.19 11.06 1.17 1.94 1.92 0.85
Price to Revenue (P/Rev)		 0.96 3.62 0.85 0.12 0.23 0.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 1.19 0.92 2.53 0.56
Enterprise Value to Revenue (EV/Rev)		 0.53 2.74 0.13 0.20 0.18 0.12
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.29 0.29 0.81 0.92 0.44
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.92 0.44
Financial Leverage		 -1.39 -1.71 -1.20 -0.64 0.07 -0.24
Leverage Ratio		 4.14 4.51 2.96 2.75 5.42 3.40
Compound Leverage Factor		 5.62 4.55 0.83 4.52 6.26 3.55
Debt to Total Capital		 0.00% 22.24% 22.52% 44.89% 48.04% 30.45%
Short-Term Debt to Total Capital		 0.00% 22.24% 22.52% 44.89% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 48.04% 30.45%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 77.76% 77.48% 55.11% 51.96% 69.55%
Debt to EBITDA		 0.00 -0.09 -7.03 -0.35 -0.29 -0.50
Net Debt to EBITDA		 0.00 0.58 21.07 -0.22 0.13 0.20
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.29 -0.50
Debt to NOPAT		 0.00 -0.18 -0.53 -0.25 -0.34 -0.58
Net Debt to NOPAT		 0.00 1.21 1.60 -0.16 0.15 0.23
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.34 -0.58
Altman Z-Score		 -1.36 -1.95 -0.70 -4.90 -7.29 -5.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 4.43 3.36 2.06 1.28 1.72 1.52
Quick Ratio		 2.57 2.67 1.68 0.36 0.93 1.15
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.93 -26 -20 -7.39 -14
Operating Cash Flow to CapEx		 0.00% -242,863.64% -42,628.95% -497,900.00% -102,700.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -28.86 -133.52 0.00 -23.39 0.00
Operating Cash Flow to Interest Expense		 -4.31 -77.66 -83.07 0.00 -32.50 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.31 -77.69 -83.27 0.00 -32.53 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.78 0.62 0.55 0.86 1.49 1.65
Accounts Receivable Turnover		 5.73 3.07 2.89 5.42 7.12 6.62
Inventory Turnover		 0.00 0.00 0.00 1.93 2.12 2.72
Fixed Asset Turnover		 50.94 75.67 121.76 201.60 348.79 37.27
Accounts Payable Turnover		 0.00 0.00 0.00 1.29 1.49 0.95
Days Sales Outstanding (DSO)		 63.69 119.04 126.26 67.32 51.23 55.16
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 189.11 172.17 134.36
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 281.92 244.87 383.44
Cash Conversion Cycle (CCC)		 63.69 119.04 126.26 -25.49 -21.47 -193.92
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -2.25 -9.97 3.06 7.28 2.62 8.67
Invested Capital Turnover		 -8.37 -3.95 -8.31 6.59 7.54 7.39
Increase / (Decrease) in Invested Capital		 0.00 -7.71 13 4.21 -4.66 6.05
Enterprise Value (EV)		 9.92 66 3.66 6.69 6.63 4.83
Market Capitalization		 18 87 24 4.20 8.45 6.64
Book Value per Share		 $0.25 $0.98 $0.89 $3.16 $0.57 $0.90
Tangible Book Value per Share		 $0.09 $0.68 $0.78 $1.43 $0.57 $0.67
Total Capital		 5.83 15 31 8.70 8.53 15
Total Debt		 0.00 3.24 6.94 3.90 4.10 4.59
Total Long-Term Debt		 0.00 0.00 0.00 0.00 4.10 4.59
Net Debt		 -8.08 -21 -21 2.48 -1.81 -1.81
Capital Expenditures (CapEx)		 0.00 0.01 0.04 0.01 0.01 -3.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.08 11 1.43 7.47 2.77 -0.21
Debt-free Net Working Capital (DFNWC)		 15 36 29 8.89 8.68 6.19
Net Working Capital (NWC)		 15 33 22 4.99 8.68 6.19
Net Nonoperating Expense (NNE)		 4.26 20 -12 4.26 5.71 2.59
Net Nonoperating Obligations (NNO)		 -8.08 -21 -21 2.48 -1.81 -1.81
Total Depreciation and Amortization (D&A)		 0.56 0.54 1.17 1.06 1.15 0.87
Debt-free, Cash-free Net Working Capital to Revenue		 37.54% 46.81% 4.99% 21.92% 7.41% -0.51%
Debt-free Net Working Capital to Revenue		 80.41% 148.66% 101.79% 26.10% 23.26% 14.84%
Net Working Capital to Revenue		 80.41% 135.21% 77.58% 14.64% 23.26% 14.84%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($85.60) ($0.60) ($13.02) ($3.22) ($1.04)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 440.41K 1.06M 1.55M 5.52M 10.17M
Adjusted Diluted Earnings per Share		 $0.00 ($85.60) $0.00 ($13.02) ($3.22) ($1.04)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 440.41K 1.33M 1.55M 5.52M 10.17M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($85.60) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 440.41K 1.33M 5.09M 8.87M 11.65M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.83 -18 -16 -16 -12 -7.94
Normalized NOPAT Margin		 -30.95% -75.09% -54.64% -46.39% -32.28% -19.05%
Pre Tax Income Margin		 -57.95% -156.25% -2.12% -59.04% -47.53% -25.20%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -2.81 -108.47 -11.08 0.00 -48.65 0.00
NOPAT to Interest Expense		 -2.34 -51.28 -66.70 0.00 -38.12 0.00
EBIT Less CapEx to Interest Expense		 -2.81 -108.50 -11.27 0.00 -48.68 0.00
NOPAT Less CapEx to Interest Expense		 -2.34 -51.31 -66.90 0.00 -38.16 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Biofrontera

This table displays calculated financial ratios and metrics derived from Biofrontera's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 1,367,628.00 1,517,628.00 5,089,413.00 5,089,413.00 5,543,518.00 7,749,211.00 8,873,932.00 9,446,197.00 10,668,442.00 11,648,323.00 11,648,323.00
DEI Adjusted Shares Outstanding		 1,367,628.00 1,517,628.00 5,089,413.00 5,089,413.00 5,543,518.00 7,749,211.00 8,873,932.00 9,446,197.00 10,668,442.00 11,648,323.00 11,648,323.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.64 2.32 -2.05 -0.05 -1.02 -0.18 -0.47 -0.56 -0.62 0.48 -0.41
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 105.83% 4.44% -9.40% 34.05% 1.30% 18.54% 8.54% 15.19% -22.46% 36.16% 17.42%
EBITDA Growth		 -59.32% 229.45% -98.75% 108.51% -43.47% -123.60% 53.87% -828.45% -18.02% 626.41% -14.46%
EBIT Growth		 -61.03% 200.49% -93.82% 104.51% -42.26% -130.04% 52.98% -1,491.42% -15.18% 524.47% -12.91%
NOPAT Growth		 -26.96% 1.56% 0.46% 41.71% -7.36% 69.05% 16.83% -0.16% -26.57% 480.24% 4.99%
Net Income Growth		 -147.16% 226.61% -39.57% 97.39% 10.61% -139.59% 59.73% -1,971.60% -17.29% 504.01% -13.06%
EPS Growth		 -105.31% 186.69% 0.00% 99.31% 78.88% -110.96% 83.68% -1,040.00% 36.73% 348.00% 12.77%
Operating Cash Flow Growth		 66.27% -7.19% 9.87% 54.33% 39.72% 88.53% -23.82% 35.49% -216.47% -133.63% 98.30%
Free Cash Flow Firm Growth		 59.51% 52.34% 118.95% 101.72% 63.72% 142.78% -530.35% 1,891.68% 93.21% -143.14% 51.18%
Invested Capital Growth		 289.35% 137.47% -224.20% -37.52% -16.78% -64.00% 186.88% -211.15% -158.36% 230.97% 54.22%
Revenue Q/Q Growth		 52.12% 19.09% -25.32% -0.92% 14.96% 39.35% -31.61% 5.15% -22.61% 144.69% -41.03%
EBITDA Q/Q Growth		 53.36% 228.83% -274.71% 108.11% -885.92% 78.81% -241.46% -28.07% -27.33% 194.53% -174.25%
EBIT Q/Q Growth		 51.74% 213.32% -292.92% 104.28% -1,620.64% 76.08% -201.99% -26.65% -25.88% 188.17% -180.33%
NOPAT Q/Q Growth		 46.89% -19.75% 1.18% 7.24% 2.19% 65.48% -165.60% -11.70% -23.61% 203.69% -166.36%
Net Income Q/Q Growth		 35.53% 155.60% -396.00% 97.54% -2,105.84% 75.37% -201.07% -26.67% -24.89% 184.82% -184.26%
EPS Q/Q Growth		 35.82% 149.14% -226.32% 98.26% -1,860.00% 74.49% -88.00% -21.28% -8.77% 200.00% -166.13%
Operating Cash Flow Q/Q Growth		 80.61% -342.42% 62.50% -41.95% 74.41% 15.81% -304.82% 26.04% -25.55% 37.85% 97.05%
Free Cash Flow Firm Q/Q Growth		 74.44% 0.17% 127.04% -75.10% -639.78% 217.72% -372.01% 215.23% -101.84% -647.59% -207.80%
Invested Capital Q/Q Growth		 -70.83% 128.59% -145.78% 304.68% -61.15% -1.13% 10.50% -361.85% 79.60% 660.67% -48.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 48.40% 49.33% 47.98% 44.61% 45.88% 58.02% 61.95% 70.74% 70.74% 82.40% 79.02%
EBITDA Margin		 -42.00% 45.43% -106.28% 8.70% -59.48% -9.05% -45.17% -55.02% -90.53% 34.97% -44.03%
Operating Margin		 -51.93% -36.49% -69.10% -64.69% -55.04% -13.63% -52.95% -56.25% -89.84% 26.64% -42.84%
EBIT Margin		 -44.82% 42.65% -110.16% 4.76% -62.94% -10.81% -47.72% -57.48% -93.49% 33.69% -45.88%
Profit (Net Income) Margin		 -71.29% 33.28% -131.91% -3.28% -62.91% -11.12% -48.94% -58.96% -95.15% 32.98% -47.12%
Tax Burden Percent		 100.02% 100.17% 100.01% 108.44% 100.05% 99.86% 99.98% 100.40% 100.09% 100.02% 100.00%
Interest Burden Percent		 159.04% 77.91% 119.73% -63.54% 99.89% 103.02% 102.59% 102.18% 101.68% 97.90% 102.70%
Effective Tax Rate		 0.00% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% 0.00%
Return on Invested Capital (ROIC)		 -1,627.48% -240.90% 0.00% -180.01% -467.14% -71.99% 0.00% 0.00% -4,237.83% 196.94% -352.19%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,599.39% -321.62% 0.00% -2,040.29% 129.87% -131.06% 0.00% 0.00% -3,993.58% 137.19% -774.68%
Return on Net Nonoperating Assets (RNNOA)		 1,497.74% 205.63% 0.00% 39.94% -14.55% -9.50% 0.00% 0.00% 2,499.88% -33.36% -96.91%
Return on Equity (ROE)		 -129.74% -35.27% -309.83% -140.07% -481.69% -81.49% 1,673.93% -531.54% -1,737.95% 163.58% -449.09%
Cash Return on Invested Capital (CROIC)		 -690.09% -388.51% 0.00% -104.04% -446.53% -149.37% -609.12% 0.00% 0.00% -247.94% -254.28%
Operating Return on Assets (OROA)		 -33.80% 36.87% -110.10% 5.73% -84.58% -16.12% -88.10% -107.98% -204.79% 55.46% -95.82%
Return on Assets (ROA)		 -53.76% 28.78% -131.83% -3.95% -84.54% -16.58% -90.35% -110.77% -208.43% 54.30% -98.41%
Return on Common Equity (ROCE)		 -129.74% -35.27% -235.62% -140.07% -481.69% -81.49% 6,013.74% -531.54% -1,737.95% 163.58% -449.09%
Return on Equity Simple (ROE_SIMPLE)		 -2,547.40% 0.00% 426.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.23 -3.87 -3.83 -3.55 -3.47 -1.20 -3.18 -3.56 -4.39 4.56 -3.02
NOPAT Margin		 -36.35% -36.55% -48.37% -45.28% -38.53% -9.54% -37.06% -39.37% -62.89% 26.65% -29.99%
Net Nonoperating Expense Percent (NNEP)		 -28.09% 80.72% -85.00% 1,860.28% -597.01% 59.07% 217.04% -50.51% -244.25% 59.75% 422.49%
Return On Investment Capital (ROIC_SIMPLE)		 - -44.53% 125.02% -31.67% -62.78% -14.05% -67.92% 1,077.36% -233.63% 30.24% -28.03%
Cost of Revenue to Revenue		 51.60% 50.67% 52.02% 55.39% 54.12% 41.98% 38.05% 29.26% 29.26% 17.60% 20.98%
SG&A Expenses to Revenue		 97.72% 85.51% 116.86% 101.38% 93.50% 65.42% 100.84% 117.35% 148.35% 51.19% 109.04%
R&D to Revenue		 0.37% 0.31% 0.21% 7.92% 7.42% 6.23% 14.05% 9.63% 12.22% 4.61% 8.93%
Operating Expenses to Revenue		 100.34% 85.82% 117.08% 109.30% 100.92% 71.65% 114.89% 126.99% 160.58% 55.80% 121.86%
Earnings before Interest and Taxes (EBIT)		 -3.99 4.52 -8.72 0.37 -5.67 -1.36 -4.10 -5.19 -6.53 5.76 -4.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.74 4.81 -8.41 0.68 -5.36 -1.14 -3.88 -4.97 -6.33 5.98 -4.44
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 11.56 0.88 0.00 0.42 1.33 1.91 15.14 0.00 0.00 0.63 1.55
Price to Tangible Book Value (P/TBV)		 0.00 1.94 0.00 0.54 1.34 1.92 16.21 0.00 0.00 0.85 2.72
Price to Revenue (P/Rev)		 0.36 0.12 0.24 0.13 0.21 0.23 0.19 0.17 0.28 0.16 0.22
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.44 0.92 0.00 0.07 1.70 2.53 3.29 0.00 0.00 0.56 1.75
Enterprise Value to Revenue (EV/Rev)		 0.42 0.20 0.30 0.01 0.13 0.18 0.25 0.10 0.31 0.12 0.18
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.28 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 8.58 0.81 -1.28 0.03 0.00 0.92 8.99 -0.93 -1.73 0.44 0.78
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.92 8.99 -0.93 -1.73 0.44 0.78
Financial Leverage		 -0.94 -0.64 -1.04 -0.02 -0.11 0.07 -0.68 -1.12 -0.63 -0.24 0.13
Leverage Ratio		 3.77 2.75 4.46 3.23 8.01 5.42 -29.89 6.68 11.51 3.40 6.33
Compound Leverage Factor		 6.00 2.14 5.35 -2.05 8.00 5.59 -30.67 6.83 11.70 3.33 6.50
Debt to Total Capital		 89.56% 44.89% 462.67% 2.64% 0.00% 48.04% 89.99% -1,314.55% 237.21% 30.45% 43.74%
Short-Term Debt to Total Capital		 89.56% 44.89% 462.67% 2.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 48.04% 89.99% -1,314.55% 237.21% 30.45% 43.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 701.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 10.44% 55.11% -1,064.05% 97.36% 100.00% 51.96% 10.01% 1,414.55% -137.21% 69.55% 56.26%
Debt to EBITDA		 -0.45 -0.35 -0.15 -0.04 0.00 -0.29 -0.44 -0.28 -0.27 -0.50 -0.48
Net Debt to EBITDA		 -0.11 -0.22 0.10 0.62 0.00 0.13 -0.25 0.19 -0.06 0.20 0.16
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.29 -0.44 -0.28 -0.27 -0.50 -0.48
Debt to NOPAT		 -0.52 -0.25 -0.15 -0.02 0.00 -0.34 -0.37 -0.38 -0.36 -0.58 -0.61
Net Debt to NOPAT		 -0.13 -0.16 0.09 0.31 0.00 0.15 -0.21 0.26 -0.08 0.23 0.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.34 -0.37 -0.38 -0.36 -0.58 -0.61
Altman Z-Score		 -3.40 -2.92 -5.61 -4.76 -7.15 -5.19 -8.21 -7.62 -10.62 -3.67 -5.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 23.95% 0.00% 0.00% 0.00% -259.26% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.02 1.28 1.44 1.89 1.53 1.72 1.40 0.96 1.15 1.52 1.20
Quick Ratio		 0.46 0.36 0.54 0.85 0.70 0.93 0.53 0.57 0.51 1.15 0.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.10 -8.08 2.19 0.54 -2.94 3.46 -9.41 11 -0.20 -1.49 -4.59
Operating Cash Flow to CapEx		 0.00% 0.00% -5,833.33% -236,000.00% 0.00% 0.00% -137,233.33% -304,500.00% 0.00% 0.00% -1,400.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 6.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -10.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -10.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.75 0.86 1.00 1.21 1.34 1.49 1.85 1.88 2.19 1.65 2.09
Accounts Receivable Turnover		 5.81 5.42 5.75 7.27 6.21 7.12 9.84 10.51 9.45 6.62 10.92
Inventory Turnover		 0.86 1.93 2.50 1.97 1.66 2.12 2.64 4.03 2.44 2.72 2.53
Fixed Asset Turnover		 177.89 201.60 209.78 255.37 299.64 348.79 424.55 567.94 728.71 37.27 38.68
Accounts Payable Turnover		 0.72 1.29 1.42 1.48 1.25 1.49 1.65 1.69 1.17 0.95 0.94
Days Sales Outstanding (DSO)		 62.81 67.32 63.43 50.22 58.74 51.23 37.09 34.74 38.64 55.16 33.42
Days Inventory Outstanding (DIO)		 425.50 189.11 146.06 185.62 220.47 172.17 138.03 90.62 149.77 134.36 144.30
Days Payable Outstanding (DPO)		 507.21 281.92 257.42 246.82 292.96 244.87 221.19 216.09 311.93 383.44 389.66
Cash Conversion Cycle (CCC)		 -18.90 -25.49 -47.93 -10.98 -13.75 -21.47 -46.07 -90.74 -123.52 -193.92 -211.95
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 3.18 7.28 -3.33 6.82 2.65 2.62 2.89 -7.58 -1.55 8.67 4.46
Invested Capital Turnover		 44.77 6.59 -102.47 3.98 12.13 7.54 -173.90 -103.13 67.39 7.39 11.74
Increase / (Decrease) in Invested Capital		 4.86 4.21 -6.01 -4.09 -0.53 -4.66 6.23 -14 -4.20 6.05 1.57
Enterprise Value (EV)		 14 6.69 9.92 0.48 4.49 6.63 9.52 3.81 12 4.83 7.82
Market Capitalization		 12 4.20 7.84 4.57 7.37 8.45 7.10 6.72 11 6.64 9.42
Book Value per Share		 $0.76 $3.16 ($1.06) $2.14 $1.00 $0.57 $0.05 ($0.49) ($0.24) $0.90 $0.52
Tangible Book Value per Share		 ($1.23) $1.43 ($1.57) $1.66 $0.99 $0.57 $0.05 ($0.50) ($0.24) $0.67 $0.30
Total Capital		 9.95 8.70 0.51 11 5.53 8.53 4.69 -0.33 1.88 15 11
Total Debt		 8.91 3.90 2.36 0.30 0.00 4.10 4.22 4.34 4.46 4.59 4.72
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 4.10 4.22 4.34 4.46 4.59 4.72
Net Debt		 2.15 2.48 -1.49 -4.09 -2.88 -1.81 2.43 -2.91 1.04 -1.81 -1.61
Capital Expenditures (CapEx)		 0.00 -0.01 0.06 0.00 0.00 -0.05 0.00 0.00 -0.00 -0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.63 7.47 4.63 4.11 3.02 2.77 2.58 -8.12 -1.57 -0.21 -4.09
Debt-free Net Working Capital (DFNWC)		 9.40 8.89 8.47 8.50 5.90 8.68 4.37 -0.87 1.86 6.19 2.24
Net Working Capital (NWC)		 0.49 4.99 6.12 8.20 5.90 8.68 4.37 -0.87 1.86 6.19 2.24
Net Nonoperating Expense (NNE)		 3.11 -7.40 6.61 -3.29 2.20 0.20 1.02 1.77 2.25 -1.08 1.73
Net Nonoperating Obligations (NNO)		 2.15 2.48 -1.49 -4.09 -2.88 -1.81 2.43 -2.91 1.04 -1.81 -1.61
Total Depreciation and Amortization (D&A)		 0.25 0.30 0.31 0.31 0.31 0.22 0.22 0.22 0.21 0.22 0.19
Debt-free, Cash-free Net Working Capital to Revenue		 7.83% 21.92% 13.94% 11.66% 8.54% 7.41% 6.79% -20.72% -4.22% -0.51% -9.47%
Debt-free Net Working Capital to Revenue		 27.94% 26.10% 25.49% 24.12% 16.68% 23.26% 11.51% -2.23% 5.00% 14.84% 5.18%
Net Working Capital to Revenue		 1.45% 14.64% 18.40% 23.28% 16.68% 23.26% 11.51% -2.23% 5.00% 14.84% 5.18%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.64) $2.28 $0.00 ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41)
Adjusted Weighted Average Basic Shares Outstanding		 1.37M 1.55M 5.09M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M
Adjusted Diluted Earnings per Share		 ($4.64) $2.28 $0.00 ($0.05) ($0.98) ($0.25) ($0.47) ($0.57) ($0.62) $0.62 ($0.41)
Adjusted Weighted Average Diluted Shares Outstanding		 1.37M 1.55M 5.09M 5.09M 5.77M 5.52M 8.87M 9.35M 10.78M 10.17M 11.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $2.28 $0.00 $0.00 $0.00 ($0.25) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.52M 5.09M 5.09M 5.54M 7.75M 8.87M 9.45M 10.67M 11.65M 11.65M 12.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.09 -2.71 -3.83 -3.55 -3.47 -1.20 -3.18 -3.56 -4.39 3.19 -3.02
Normalized NOPAT Margin		 -34.78% -25.54% -48.37% -45.28% -38.53% -9.54% -37.06% -39.37% -62.89% 18.65% -29.99%
Pre Tax Income Margin		 -71.28% 33.23% -131.90% -3.02% -62.87% -11.13% -48.95% -58.73% -95.06% 32.98% -47.12%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -27.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -12.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -27.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -12.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Biofrontera (NASDAQ:BFRI) shows a mixed but improving operating trend, though profitability remains elusive and the balance sheet is still highly leveraged relative to equity. Over the past year, revenue has been volatile but generally above 2024 levels, while losses have narrowed from the very large losses seen in early 2024. That said, operating expenses are still consuming gross profit, and the company remains dependent on financing and balance sheet maneuvers to support liquidity.

  • Revenue improved versus early 2024 levels. Q1 2026 revenue was $10.1 million, up from $8.6 million in Q1 2025 and above the $7.9 million level in Q1 2024.
  • Gross profit continues to scale with sales. Q1 2026 gross profit was $8.0 million, indicating the business is still generating meaningful product margin before overhead.
  • Net loss improved sharply from a year ago. Q1 2026 net loss was $4.8 million, narrower than the $10.4 million loss in Q1 2024.
  • Quarter-end cash increased materially from the prior year. Cash and equivalents rose to $6.3 million in Q1 2026 from $1.8 million in Q1 2025.
  • Common equity turned positive in Q1 2026. Total common equity was $6.1 million, a major improvement from the negative equity position seen in several prior quarters.
  • Working capital appears supported by receivables and inventory. At Q1 2026, accounts receivable were $3.9 million and inventory was $1.2 million, suggesting a still-active operating base.
  • Cash flow from operations was nearly breakeven in Q1 2026. Operating cash flow was -$70,000, a better result than the larger outflows seen in 2024 and 2025 quarters.
  • Financing activity was flat in Q1 2026. No cash was raised from financing in the quarter, so liquidity gains came mostly from operating balance sheet movements rather than new funding.
  • Operating expenses still exceed gross profit. Q1 2026 operating expenses were $12.3 million versus gross profit of $8.0 million, producing a $4.3 million operating loss.
  • SG&A remains very heavy. Selling, general and administrative expense was $11.0 million in Q1 2026, far above revenue growth and the main reason the company stayed deeply unprofitable.
  • Biofrontera is still losing money each quarter. Despite some improvement, Q1 2026 posted a net loss of $4.8 million.
  • Balance sheet leverage is still significant. Total liabilities were $18.7 million versus $6.1 million of common equity in Q1 2026, leaving the company with a debt-and-liability burden that investors should watch closely.
  • Accounts payable remain elevated. Accounts payable were $10.4 million in Q1 2026, which may indicate ongoing pressure on short-term obligations and supplier financing.

Bottom line: Biofrontera has made progress on revenue and balance sheet repair, but the business is not yet consistently profitable and still carries meaningful liquidity and leverage risk. Investors will likely want to see continued revenue growth, tighter operating costs, and sustained positive operating cash flow before the turnaround looks durable.

07/22/26 03:31 AM ETAI Generated. May Contain Errors.

Biofrontera Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Biofrontera's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Biofrontera's net income appears to be on a downward trend, with a most recent value of -$10.54 million in 2025, falling from -$10.99 million in 2020. The previous period was -$17.76 million in 2024.

Biofrontera's total operating income in 2025 was -$11.35 million, based on the following breakdown:
  • Total Gross Profit: $30.74 million
  • Total Operating Expenses: $42.09 million

Over the last 5 years, Biofrontera's total revenue changed from $18.85 million in 2020 to $41.71 million in 2025, a change of 121.3%.

Biofrontera's total liabilities were at $18.08 million at the end of 2025, a 2.4% increase from 2024, and a 1.2% decrease since 2020.

In the past 5 years, Biofrontera's cash and equivalents has ranged from $1.34 million in 2023 to $24.55 million in 2021, and is currently $6.39 million as of their latest financial filing in 2025.

Over the last 5 years, Biofrontera's book value per share changed from 0.25 in 2020 to 0.90 in 2025, a change of 253.8%.


Related Companies

Financial statements for NASDAQ:BFRIW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
What most options traders never learn before their first trade
Most options losses don't come from picking the wrong trade - they come from traders who never understood how ...
Base Camp Trading | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
30-Year market veteran reveals America’s #1 Stock
Market veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...
Eagle Publishing | Sponsoredtc pixel
Forget SpaceX… this is the REAL #1 IPO of 2026
While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...
The Oxford Club | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel